Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| ACTIVE BIOTECH Aktien jetzt im kostenlosen Demokonto handeln! | LYNX | |||
► Artikel lesen | ||||
| 09.08. | Active Biotech AB - Interim Report January - June 2018 | 6 | GlobeNewswire (Europe) | |
| Second quarter in brief
The company's... ► Artikel lesen | ||||
| 31.07. | Active Bio and Teva's laquinimod fails once more, now in Huntington's disease | 24 | FierceBiotech | |
► Artikel lesen | ||||
| 31.07. | Active Biotech provides update on laquinimod in Huntington's disease | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Lund Sweden, July 31, 2018 -Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical... ► Artikel lesen | ||||
| 31.05. | Number of shares and votes in Active Biotech | 8 | GlobeNewswire (Europe) | |
| The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 145,236,480 shares... ► Artikel lesen | ||||
| 18.05. | Annual General Meeting of Active Biotech AB | 7 | GlobeNewswire (Europe) | |
| PRESS RELEASE
The Annual General Meeting of Active Biotech was held on May 17, 2018.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be... ► Artikel lesen | ||||
| 17.05. | Active Biotech AB Interim report January - March 2018 | 3 | GlobeNewswire (Europe) | |
| First quarter in brief
Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
Patent... ► Artikel lesen | ||||
| 04.05. | Nasdaq Stockholm AB: Delisting of paid subscription shares in Active Biotech AB (62/18) | 2 | GlobeNewswire | |
| The paid subscription shares in Active Biotech AB will be delisted. Last
trading day for ACTI BTA is May 8, 2018.
Instrument: Paid subscription shares
---------------------------------------
Short... ► Artikel lesen | ||||
| 23.04. | Annual Report 2017 Active Biotech AB (publ) | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com (http://www.activebiotech.com).
The Annual Report will only be... ► Artikel lesen | ||||
| 18.04. | Active Biotech: Notice of Annual General Meeting of Shareholders | 8 | GlobeNewswire (Europe) | |
| The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 17, 2018, at 5 pm at the company's offices, Scheelevägen... ► Artikel lesen | ||||
| 16.04. | BRIEF-Active Biotech says rights issue oversubscribed | - | Reuters.com | |
► Artikel lesen | ||||
| 12.04. | Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer | 9 | GlobeNewswire (Europe) | |
| PRESS RELEASELund, April 12, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at... ► Artikel lesen | ||||
| 27.03. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares in Active Biotech AB (38/18) | 6 | GlobeNewswire | |
| With effect from March 28, 2018, the subscription rights in Active Biotech AB
will be quoted on the list for Equity rights. Quotation will continue up until
and including April 9, 2018.
Instrument:... ► Artikel lesen | ||||
| 22.03. | NASDAQ OMX Nordic: Derivatives: Adjustment in Active Biotech due to rights issue (02/18) | 4 | GlobeNewswire | |
| Extraordinary General Meeting (EGM) of Active Biotech AB (Active Biotech) held
on March 19, 2018, approved a rights issue whereby shareholders are entitled to
one (1) new share for every two (2) shares... ► Artikel lesen | ||||
| 22.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 23.03.2018 - 1 | 55 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 22.03.2018 CUM KAPITALMASSNAHME UND AM 23.03.2018 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 22.03.2018 AND EX CAPITAL ADJUSTMENT... ► Artikel lesen | ||||
| 15.02. | NASDAQ OMX Nordic: Derivatives: Anticipated adjustment in Active Biotech due to rights issue (01/18) | 6 | GlobeNewswire | |
| The following information is based on a press release from Active Biotech AB
(Active Biotech) published on February 15, 2018 and may be subject to change.
The board of Active Biotech has proposed... ► Artikel lesen | ||||
| 15.02. | Active Biotech: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING | 10 | GlobeNewswire (Europe) | |
| The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Monday 19 March 2018, at 5 pm at the company's offices, Scheelevägen 22 in Lund... ► Artikel lesen | ||||
| 15.02. | Active Biotech AB Year-end report January - December 2017 | 5 | GlobeNewswire (Europe) | |
| Fourth quarter in brief
The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS
Patent regarding tasquinimod for the... ► Artikel lesen | ||||
| 20.12.17 | Active Biotech: Active Biotech provides updated information about the company's financial position | 7 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech has received a waiver (exemption) from its commitment to the bank that finances the company's property in Lund that the company's liquidity should never fall below... ► Artikel lesen | ||||
| 07.12.17 | Active Biotech: Active Biotech provides updated information about the company's financial position - the company currently lacks funding to ensure its operations for the coming twelve-month period | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech (Nasdaq Stockholm: ACTI) provides updated information about the company's financial situation. As informed by the company in the interim report for January-September... ► Artikel lesen | ||||
| 01.12.17 | Active Biotech: Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS | 14 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech (Nasdaq Stockholm: ACTI) today announced initial results from the Phase II proof of concept study of laquinimod in Primary Progressive MS (PPMS) sponsored by Active... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 20,41 | +0,54 % | Leerverkäufer-Alarm! Deutliche Bewegung bei K+S und Leoni sowie Deutsche Bank und Evotec - spürbarer Aufbau bei Thyssenkrupp und Osram - markanter Abbau bei Ceconomy und Bilfinger sowie Aurelius - insgesamt 17 Veränderungen! | |
| Hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 15. August Seit geraumer Zeit sind die Aktien deutscher Unternehmen verstärkt ins... ► Artikel lesen | ||||
| MEDIGENE | 14,50 | +7,65 % | Maydorns Meinung: Tesla, BYD, Bayer, Nordex, JinkoSolar, Evotec, Medigene | |
| In Maydorns Meinung analysiert Börsenexperte Alfred Maydorn die neuesten Entwicklungen der beliebtesten Aktien deutscher Anleger - und versieht sie mit seiner persönlichen Meinung. In dieser Ausgabe... ► Artikel lesen | ||||
| MORPHOSYS | 100,50 | +0,55 % | MorphoSys: Die schlechteste Analystin schlägt wieder zu! | |
| Ich habe vor einigen Monaten an dieser Stelle bereits einen Artikel über die Aktie des deutschen Biotechnologie-Unternehmens MorphoSys sowie die HSBC-Analystin Julie Mead geschrieben. Diese hatte damals... ► Artikel lesen | ||||
| BB BIOTECH | 58,95 | +0,60 % | BB Biotech Top-Beteiligung Vertex: Tuchfühlung zum Allzeithoch - Kursgewinn über 80% | |
| Der mit einem Anteil von 6,5 Prozent fünftgrößte Wert im Portfolio von BB Biotech, Vertex, entwickelt sich weiterhin hervorragend. Zuletzt hat das Unternehmen gemeldet, dass die amerikanische Gesundheitsbehörde... ► Artikel lesen | ||||
| QIAGEN | 33,23 | +0,54 % | QIAGEN: Leerverkäufer BNP PARIBAS legt den Rückwärtsgang ein! | |
| KJ Venlo (www.aktiencheck.de) - Leerverkäufer BNP PARIBAS SA baut Netto-Leerverkaufsposition in Aktien der QIAGEN N.V. jetzt ab: Die Leerverkäufer des Hedgefonds BNP PARIBAS SA legen den Rückwärtsgang... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage